Brooks Laboratories Share Price | Brooks Laboratories Stock Screener
BROOKS
Pharmaceuticals
Share Price NSE
₹72.07
▲
0.45 (0.63%)
Share Price BSE
₹51.53
▲
2.33 (4.74%)
As of April 15, 2026, the Brooks Laboratories share price (NSE: BROOKS) is ₹72.07 on NSE and ₹51.53 on BSE, up 0.63% from the previous close, with shares trading between ₹70.02 and ₹76.82, and a 52-week range of ₹37.11–₹160.19.
Check BROOKS price range for the annual price range and momentum.
Use the Brooks Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Brooks Laboratories Market Cap
₹137.30 Cr.
BROOKS P/E Ratio (TTM)
6.60
Brooks Laboratories P/B Ratio
1.23
EPS (TTM)
₹-3.72
Dividend Yield
-
Debt to Equity
0.08
BROOKS 52 Week High
₹160.19
Brooks Laboratories 52 Week Low
₹37.11
Operating Margin
-5.00%
Profit Margin
-8.33%
BROOKS Revenue (TTM)
₹24.00
EBITDA
₹-1.00
Net Income
₹-2.00
Total Assets
₹124.00
Total Equity
₹98.00
Brooks Laboratories Share Price Chart
Screen Brooks Laboratories share price with an interactive chart. Analyse BROOKS price trends and volatility across different timeframes.
Brooks Laboratories Company Profile - Fundamental Screener
Screen Brooks Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BROOKS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE650L01011
Brooks Laboratories Balance Sheet Screener
Screen BROOKS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 124 | 90 | 110 | 196 | 162 |
| Current Assets | 34 | 31 | 28 | 61 | 47 |
| Fixed Assets | 14 | 14 | 15 | 110 | 108 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3 | 2 | 3 | 13 | 19 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 98 | 66 | 74 | 134 | 79 |
| Share Capital | 30 | 26 | 25 | 25 | 25 |
| Reserves & Surplus | 69 | 39 | 49 | 63 | 54 |
Brooks Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Brooks Laboratories income statement and profit fundamentals.
Analyze BROOKS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Brooks Laboratories share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 33 | 30 | 22 | 18 | 18 | 21 | 21 | 13 | 16 | 24 | 22 | 29 | 17 | 19 |
| Expenses | 25 | 22 | 21 | 16 | 27 | 20 | 24 | 22 | 16 | 20 | 25 | 25 | 32 | 26 | 27 |
| EBITDA | -1 | 10 | 9 | 6 | -9 | -2 | -3 | -2 | -4 | -4 | -1 | -3 | -4 | -9 | -9 |
| Operating Profit % | -5.00% | 12.00% | 11.00% | 4.00% | -54.00% | -11.00% | -16.00% | -7.00% | -29.00% | -25.00% | -5.00% | -15.00% | -14.00% | -50.00% | -51.00% |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit Before Tax | -1 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -7 | -11 | -12 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -2 | -4 |
| Net Profit | -2 | 10 | 8 | 6 | -10 | -2 | -4 | -2 | -4 | -5 | -2 | -4 | -6 | -9 | -8 |
| EPS | -0.54 | 3.25 | 2.71 | 1.87 | -3.77 | -0.94 | -1.51 | -0.82 | -1.75 | -1.81 | -0.60 | -1.51 | -1.46 | -3.80 | -3.19 |
Brooks Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen BROOKS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 3 | -10 | -15 | -37 | 5 |
| Investing Activities | -45 | 0 | 1 | -25 | -5 |
| Financing Activities | 42 | 10 | 11 | 64 | 1 |
| Net Cash Flow | 0 | 0 | -3 | 2 | 1 |
Brooks Laboratories Shareholding Pattern Screener
See Brooks Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Brooks Laboratories promoter holding and ownership changes for BROOKS on TickJournal.
| Item | 2026-Mar | 2025-Jan | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 63.59% | 63.59% |
| FII Holding | 0.17% | 0.00% | 0.05% | 0.00% | 0.01% | 0.09% | 0.00% | 0.00% |
| DII Holding | 10.38% | 9.90% | 10.38% | 10.38% | 10.38% | 10.38% | 3.86% | 3.86% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.56% | 32.13% | 31.86% | 32.01% | 31.70% | 31.84% | 25.55% | 25.57% |
| Other Holding | 5.28% | 5.35% | 5.08% | 4.99% | 5.30% | 5.07% | 7.00% | 6.98% |
| Shareholder Count | 10,741 | 10,374 | 10,537 | 10,317 | 10,078 | 10,532 | 11,432 | 11,543 |
Brooks Laboratories Share Dividend Screener - Share Yield Analysis
Check Brooks Laboratories dividend history with payout and yield data.
View Brooks Laboratories dividend details including ex-dates and amounts for BROOKS stock.
Brooks Laboratories Stock Index Membership
See which indices include Brooks Laboratories stock.
Check BROOKS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Brooks Laboratories Market Events Screener - Corporate Actions
Get Brooks Laboratories corporate actions including splits, bonuses, and buybacks.
Check Brooks Laboratories stock events that may affect BROOKS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 25.21% | ||
| Annual General Meeting | NA | 6.27% | ||
| Annual General Meeting | NA | -5.83% | ||
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | -4.59% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.90% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -4.69% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -3.00% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.64% |
| 2025-01-11 | 2025-01-11 | Extraordinary General Meeting | NA | 15.99% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -4.13% |
| 2023-07-28 | 2023-07-28 | Rights | 1:16 | 12.52% |
| 2020-02-11 | Rights | 9:20 | - |
Brooks Laboratories Competitors Screener - Peer Comparison
Screen BROOKS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Brooks Laboratories Company Announcements - News Screener
Screen BROOKS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-19 | Update On Scheme Of Arrangement Involving Brooks Steriscience Limited (BSL) A Joint Venture / Associate Of The Company. | - |
| 2026-04-29 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-02 | Reply To Clarification Sought Vide Email Dated 1St April 2026 With Reference To Price Movement. | - |
| 2026-04-01 | Clarification Sought from Brooks Laboratories Ltd | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-06 | Update On Scheme Of Arrangement Involving Brooks Steriscience Limited (BSL) A Joint Venture / Associate Of The Company. | - |
| 2026-02-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-06 | Board Meeting Outcome for Outcome Of Board Meeting Held On Friday 6Th February 2026. | - |
| 2026-02-06 | Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-30 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulation 2015- ITAT Orders. | - |
| 2026-01-29 | Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015. | - |
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-24 | Closure of Trading Window | - |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-14 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 14Th November 2025. | - |
| 2025-11-14 | Results For Quarter And Half Year Ended 30Th September 2025 | - |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2025-11-07 | Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |